SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

NCT05747716 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
44
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology